BiotechTube

avdoralimab

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

COVID

Conditions

COVID

Trial Timeline

Apr 27, 2020 → Mar 30, 2021

NCT ID
NCT04371367

About avdoralimab

avdoralimab is a phase 2 stage product being developed by Innate Pharma for COVID. The current trial status is completed. This product is registered under clinical trial identifier NCT04371367. Target conditions include COVID.

What happened to similar drugs?

11 of 20 similar drugs in COVID were approved

Approved (11) Terminated (7) Active (6)
✅mRNA-1283.251 Variant-containing FormulationModernaApproved
✅Icosapent ethylAmarin CorporationApproved
✅bamlanivimabEli LillyApproved
✅AZD1222AstraZenecaApproved
✅AZD1222AstraZenecaApproved
✅COVID-19 vaccine Pfizer (3 doses) + COVID-19 vaccine Pfizer (2 doses) + COVID-19 mRNA Vaccine Moderna (3 doses) + COVID-19 mRNA Vaccine Moderna (2 doses) + COVID-19 mRNA Vaccine Moderna (1 dose)SanofiApproved
✅Rivaroxaban 10 mgBayerApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04371367Phase 2Completed

Competing Products

20 competing products in COVID

See all competitors
ProductCompanyStageHype Score
mRNA-1283.251 Variant-containing FormulationModernaApproved
0
mRNA-1283.222ModernaPhase 3
0
COVID-19 VaccineModernaPreclinical
0
mRNA-1083ModernaPhase 3
0
SPIKEVAX (mRNA-1273)ModernaPreclinical
0
Moderna COVID-19 VaccineModernaPreclinical
0
Gam-COVID-VacDr. Reddy's LaboratoriesPhase 2/3
31
AVIGAN + Placebo ComparatorDr. Reddy's LaboratoriesPhase 3
29
Favipiravir + NitazoxanideStrides PharmaPhase 2
35
Human COVID-19 immunoglobulin (pH4) for intravenous injection + PlaceboSinopharmPhase 2
31
mavrilimumabKiniksa PharmaceuticalsPhase 2/3
32
Mavrilimumab + PlaceboKiniksa PharmaceuticalsPhase 2
29
Mavrilimumab + PlacebosKiniksa PharmaceuticalsPhase 2
29
Mavrilimumab + PlacebosKiniksa PharmaceuticalsPhase 2
29
Gimsilumab + PlaceboRoivant SciencesPhase 2
32
Icosapent ethylAmarin CorporationApproved
25
Icosapent ethylAmarin CorporationPhase 2
25
Bamlanivimab + Placebo + EtesevimabEli LillyPhase 3
40
GX-03 + Petrolatum ointmentTurn TherapeuticsPhase 2
25
Cytotoxic T LymphocytesTevogen BioPhase 1
19